Nonalcoholic fatty liver disease (NAFLD) is associated with significantly higher risk of subsequent cardiovascular events in women, but not in men, according to research presented at The Liver Meeting held by the American Association for the Study of Liver Diseases.

October 20, 2017 — Digital health company Analytics 4 Life announced it has completed a $25 million Series B financing. This financing event was supported by an international syndicate of accredited investors, including physicians, healthcare professionals and medical device experts. The company's novel cardiac imaging technology is under clinical investigation to help physicians assess the presence of coronary artery disease (CAD) using intrinsic signals scanned from the body without radiation, contrast agents or cardiac stress.

October 19, 2017 — Novel smartphone and tablet applications for atrial fibrillation patients and healthcare professionals have been launched by heart experts. The objectives and design of the apps are outlined in a paper published online in EP Europace,1 with a summary published in the European Heart Journal.2

African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to women of Caucasian, Hispanic/Latina, Asian and other ethnic backgrounds, according to a new study. The study, the largest of its kind, was published in JAMA Cardiology by researchers from the Perelman school of Medicine at the University of Pennsylvania.

Endologix Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to commence a confirmatory clinical study evaluating the safety and effectiveness of the Nellix EndoVascular Aneurysm Sealing System (EVAS) for the endovascular treatment of infrarenal abdominal aortic aneurysms. The EVAS2 IDE Multicenter Safety and Effectiveness Confirmatory Study (EVAS2) will prospectively evaluate the refined Indications for Use (IFU) and the Nellix Gen2 EVAS System.

The Role of Telomere Length in Cardiovascular Risk Assessment

A new area of DNA testing involving telomere length may enhance a patient’s cardiovascular disease risk stratification.  Telomeres are biological clocks that determine the lifespan of a cell, as well as the number of times it can divide to create replacements. Telomeres are repeating units of DNA on the ends of each chromosome that protect the information encoded in the DNA against loss. Some of these repeating units are lost with each cell division, but can be restored by enzymes in the nucleus.  

October 18, 2017 — The U.S. Food and Drug Administration (FDA) recently approved a new treatment option for patients who have been diagnosed with moderate to severe central sleep apnea (CSA). The  Respicardia Remedē System is an implantable pacemaker-like device that stimulates the phrenic nerve located in the chest that is responsible for sending signals to the diaphragm to stimulate breathing.

Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-term recovery in patients who suffer neurological disability after cardiac arrest, according to a study appearing online in the journal Radiology.

October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the Xarelto vascular dose plus aspirin 100 mg once daily significantly reduced the risk of major cardiovascular events by 24 percent in patients with stable coronary and/or peripheral artery disease (CAD/PAD) compared to aspirin alone. This finding was driven by a robust 42 percent reduction in any stroke and 22 percent reduction in cardiovascular (CV) death.

Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at helping cardiologists perform a complex procedure that is quickly becoming the gold standard for treating patients with atrial fibrillation and other structural heart diseases.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now